TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05876442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy Exercise Program
Description: 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night for two months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy Exercise Program
Description: 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night for two months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy Exercise Program
Description: 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night for two months.
Study: NCT05018221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K1
Description: Vitamin K1 capsule (10mg) to be administered 3 times per week following the subject's hemodialysis session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium citrate
Description: Magnesium Citrate tablet (150mg) to be administered 3 times per per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Sodium Thiosulfate injection (25g/100ml) to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flux Dialyser
Description: Hemodialysis using a high flux dialyser.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medium Cut-off Dialyser
Description: Hemodialysis using a medium cut-off dialyser.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection (normal saline)
Description: Placebo to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection (normal saline)
Description: Placebo to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection (normal saline)
Description: Placebo to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule (Vitamin K1)
Description: Placebo to be administered 3 times per week following the subject's hemodialysis session.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule (Vitamin K1)
Description: Placebo to be administered 3 times per week following the subject's hemodialysis session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule (Vitamin K1)
Description: Placebo to be administered 3 times per week following the subject's hemodialysis session.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet (Magnesium citrate)
Description: Placebo to be administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet (Magnesium citrate)
Description: Placebo to be administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet (Magnesium citrate)
Description: Placebo to be administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
Study: NCT06147050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is an FDA-approved antidiabetic agent that manages high blood sugar levels in type 2 diabetes patients. However, emerging evidence may suggest a benefit to COVID recovery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive matching placebo control twice daily.
Study: NCT06327308

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The examination lasts between 45 minutes and one hour. The patient lies down in the MRI tube. He is fitted with headphones that muffle the noise produced by the machine and enable him to receive instructions from the technician. Four electrodes are applied to his chest to continuously record his heartbeat. Finally, his chest is covered with a plastic plate, which receives the MRI signals needed to form the image. Acquiring an MRI image takes between 2 and 20 seconds. To ensure that image quality is not impaired by respiratory movements, images are acquired in apnea. The technician will ask the patient to hold his or her breath repeatedly throughout the examination.

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Additional blood will be drawn for dosing acylcarnitines, copeptin, interleukin-6 (IL-6), LPS-Binding Protein (LBP), Phospholipid TransferProtein (PLTP)/Cholesteryl Ester Tranfer Protein (CETP) activity, and for plasma banking. The volume of blood will be 20 ml in total (5 ml for each assay) at each visit. Patients participating in this study will have 3 visits. Total blood volume will therefore be 20 x 3, or 60 ml for the 3 visits.
Study: NCT05636722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unguided web-based intervention
Description: An online unguided intervention based on Cognitive Behavioural Therapy and elements of Dialectical Behaviour Therapy, Problem Solving Therapy, and Mindfulness Based Cognitive Therapy. The intervention consists of 6 modules with each a theoretical part, a weekly assignment and (optional and mandatory) exercises. Participants are advised to complete one module weekly. The original intervention was adapted to students (language, addition of podcasts, examples that were more suited to their lives).
Study: NCT05902312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Participants will receive either rTMS or dTMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Participants will receive either rTMS or dTMS
Study: NCT05258045

Intervention type: RADIATION
Intervention: F18 FDG
Description: Radioactive material
Study: NCT05323396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiparasitic medication
Description: Participants in the parasite-positive group (based on positive result of either stool microscopy, stool PCR, or Strongyloides IgG) will be administered antiparasitic treatment. Antiparasitic medication administered will be targeted to treat the parasite identified. See detailed description of protocol for medication, dose, and frequency that will be given for each parasitic infection identified.~Participants with stool microscopy, stool PCR, and Strongyloides IgG all negative will not be administered treatment, thus will serve as controls.
Study: NCT06122480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All eligible patients with hepatic metastasis will undergo exploratory laparotomy surgery and synchronous resection of the tumor and hepatic metastases, if feasible according to the surgeon, 2-6 weeks after the last neoadjuvant chemotherapy treatment. All eligible patients with pulmonary metastasis will undergo resection of the primary tumor followed by resection of pulmonary metastases or vice versa, if feasible
Study: NCT04675151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentolamine Ophthalmic Solution 0.75%
Description: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Ophthalmic Solution 0.75%
Description: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: Pilocarpine ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine
Description: Pilocarpine ophthalmic solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Topical sterile ophthalmic solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical sterile ophthalmic solution
Study: NCT05717153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT06382454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assist-On Arm Robot Group
Description: 30 minutes of individualized trunk, lower extremity and upper extremity exercises; the other 30 minutes will be treated with the robotic system. In the robot-assisted treatment, a total of 12 movements will be used, including the movement patterns that patients have the most difficulty in daily life and two movement patterns used in the Proprioceptive Neuromuscular Facilitation approach. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: For 30 minutes, exercises including trunk, lower extremity and upper extremity exercises specific to the individual will be practiced, while the movement patterns to be used in the robotic system will be practiced in the other 30 minutes with the physiotherapist. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
Study: NCT04463368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated hepatic perfusion
Description: The procedure is performed under general anaesthesia. The caval vein is isolated infrahepatically above the renal veins and suprahepatically between the diaphragm and the pericardium. A catheter is placed in the retrohepatic portion of the caval vein for perfusion outflow. The portal vein is clamped and the proper hepatic artery is cannulated via the gastroduodenal artery. The liver perfusion is performed at a rate of 8- 9 ml/kg/min with a target liver temperature of 40 degrees Celsius. The leakage from the system was continuously recorded using Technetium labelled albumin (Vasculosis) injected into the perfusion circuit. Melphalan (1 mg/kg bodyweight divided into two doses, given 30 minutes apart) is added to the perfusion system. The perfusion is then continued for 60 minutes, after which the perfusion was discontinued.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated hepatic perfusion
Description: The procedure is performed under general anaesthesia. The caval vein is isolated infrahepatically above the renal veins and suprahepatically between the diaphragm and the pericardium. A catheter is placed in the retrohepatic portion of the caval vein for perfusion outflow. The portal vein is clamped and the proper hepatic artery is cannulated via the gastroduodenal artery. The liver perfusion is performed at a rate of 8- 9 ml/kg/min with a target liver temperature of 40 degrees Celsius. The leakage from the system was continuously recorded using Technetium labelled albumin (Vasculosis) injected into the perfusion circuit. Melphalan (1 mg/kg bodyweight divided into two doses, given 30 minutes apart) is added to the perfusion system. The perfusion is then continued for 60 minutes, after which the perfusion was discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 4 courses of ipilimumab 3mg/kg every third week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 4 courses of ipilimumab 3mg/kg every third week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 4 courses of nivolumab 1mg/kg every third week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 4 courses of nivolumab 1mg/kg every third week
Study: NCT05678751

Intervention type: DIAGNOSTIC_TEST
Intervention: lower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)
Description: Detection of pathogens and microorganisms in the lower genital tract of infertile and spontaneously pregnant women by a new MALDI-TOF MS-based technique

Intervention type: DIAGNOSTIC_TEST
Intervention: lower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)
Description: Detection of pathogens and microorganisms in the lower genital tract of infertile and spontaneously pregnant women by a new MALDI-TOF MS-based technique
Study: NCT05717153

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT05321147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lacutamab
Description: Patients will receive a fixed dose of 750mg as 1-hour IV infusion
Study: NCT05717153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT05067465

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selected food groups
Description: Food groups~1. Milk and dairy products~2. Whole-grain products (rich in soluble fibers)~3. Sausage and processed meat (pork)~4. Meat-free sausage and meat alternatives (based on egg, soy)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selected food groups
Description: Food groups~1. Milk and dairy products~2. Whole-grain products (rich in soluble fibers)~3. Sausage and processed meat (pork)~4. Meat-free sausage and meat alternatives (based on egg, soy)
Study: NCT05717153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT06594744

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic variceal ligation
Description: EVL will be performed and repeated every 3 to 4 weeks until the EVs are eradicated. Following this, patients will undergo regular upper gastrointestinal endoscopic surveillance, initially every three months for a total of two sessions, then every six months for a total of two sessions, and subsequently annually. If EVs are found to recur during surveillance, additional EVL will be performed every 3 to 4 weeks until the varices are again eradicated endoscopically.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol
Description: The initial dosage of carvedilol is set at 6.25 mg daily. In the absence of hypotension (systolic blood pressure \&lt; 90 mmHg), bradycardia (resting heart rate \&lt; 55 beats per minute), or other adverse effects, hospitalized patients may have their dosage increased to 12.5 mg daily after 3 days, while outpatient patients may increase their dosage to 12.5 mg daily after 7 days. This dosage represents the target dose for the trial.
Study: NCT06609447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: VSL#3 450 billion CFU/sachet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachets with maltose, cornstarch and dioxide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab
Description: Patients will start combined therapy with vedolizumab and VSL#3 or placebo at the same time. Vedolizumab will be administered according to clinical practice with the following schedule: 300 mg intravenously on Baseline (Day 1 / Week 0) and Weeks 2, 6, and 14, with a flexibility of ±3 days relative to the start of VSL#3 administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Patients will start combined therapy with vedolizumab and VSL#3 or placebo at the same time. Vedolizumab will be administered according to clinical practice with the following schedule: 300 mg intravenously on Baseline (Day 1 / Week 0) and Weeks 2, 6, and 14, with a flexibility of ±3 days relative to the start of VSL#3 administration.
Study: NCT06610708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Prehabilitation Program
Description: Patients begin with a one-on-one assessment by a program cardiologist and a CR nurse, followed by a symptom-limited cardiopulmonary exercise test (CPET) to tailor their exercise regimen. The exercise program, based on the FITT (frequency, intensity, time, and type) principle, includes biweekly sessions either at home or at a commercial gym, with ongoing oversight by SJHC CRSP rehabilitation trainers. Additionally, participants have access to dietary counseling to optimize heart-healthy nutrition.
Study: NCT06374173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGI-6 Injection
Description: TGI-6 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
Study: NCT05838144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acapella device
Description: Group A. Will use Acapella device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only routine chest physical therapy program
Description: Group B. Will take medications and perform routine chest physical therapy program.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Only routine chest physical therapy program
Description: Group B. Will take medications and perform routine chest physical therapy program.
Study: NCT05717153

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eflornithine
Description: Given PO
Study: NCT05125705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma injection
Description: The PRP is prepared by RegenLab's RegenKit-THT, in accordance with operating instructions supplied with the kit. The device allows automated blood collection (8 mL) and blood component separation in closed circuit. After centrifugation at room temperature for 9 minutes at centrifugal force of 1500g, the RegenTHT tube is then inverted several times before re-suspension, allowing 4mL of PRP to be obtained for each tube. 2.5mL will be injected into patients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Saline injection
Study: NCT05717153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine
Description: Given PO
Study: NCT05559008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab and Apatinib will be administered in T3.2 subtypes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Camrelizumab and Apatinib will be administered in T3.2 subtypes
Study: NCT05717153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyamine Transport Inhibitor AMXT-1501 Dicaprate
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyamine Transport Inhibitor AMXT-1501 Dicaprate
Description: Given PO
Study: NCT05213897

Intervention type: DEVICE
Intervention: SARS-CoV-2 Antigen Assay
Description: To demonstrate that non-laboratory personnel can accurately perform the SARS-CoV-2 Antigen assay in the intended use environment using nasopharyngeal samples by demonstrating that the assay can achieve a ≥ 80% sensitivity and specificity when it is compared to the results of a high sensitivity EUA SARSCoV-2 RT-PCR assay using nasopharyngeal samples.

Intervention type: DEVICE
Intervention: SARS-CoV-2 Antigen Assay
Description: To demonstrate that non-laboratory personnel can accurately perform the SARS-CoV-2 Antigen assay in the intended use environment using nasopharyngeal samples by demonstrating that the assay can achieve a ≥ 80% sensitivity and specificity when it is compared to the results of a high sensitivity EUA SARSCoV-2 RT-PCR assay using nasopharyngeal samples.
Study: NCT05916573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149
Description: single oral adminiatration, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149
Description: single oral adminiatration, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149
Description: single oral adminiatration, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149
Description: single oral adminiatration, 20mg